Baudax Bio Inc

Company Profile

Baudax Bio Inc had its IPO on 2019-11-22 under the ticker symbol BXRX.

The company operates in the Healthcare sector and Biotechnology industry. Baudax Bio Inc has a staff strength of 9 employees.

Stock update

Shares of Baudax Bio Inc opened at $0.52 at the start of the last trading session i.e. 2023-06-02.

The stocks traded within a range of $0.52 - $0.56, and closed at $0.55.

This is a +5.77% increase from the previous day's closing price.

A total volume of 391,509 shares were traded at the close of the day’s session.

In the last one week, shares of Baudax Bio Inc have increased by +0.73%.

Baudax Bio Inc's Key Ratios

Baudax Bio Inc has a market cap of $3.15 million, indicating a price to book ratio of 0.6815 and a price to sales ratio of 1.0493.

In the last 12-months Baudax Bio Inc’s revenue was $1.27 million with a gross profit of $-5740000 and an EBITDA of $-32649000. The EBITDA ratio measures Baudax Bio Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Baudax Bio Inc’s operating margin was -2584.95% while its return on assets stood at -73.38% with a return of equity of -4772.59%.

In Q1, Baudax Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 22.5%.

Baudax Bio Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-99.6 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Baudax Bio Inc’s profitability.

Baudax Bio Inc stock is trading at a EV to sales ratio of 3.9179 and a EV to EBITDA ratio of -1.6268. Its price to sales ratio in the trailing 12-months stood at 1.0493.

Baudax Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$7.07 million

Total Liabilities

$12.37 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Baudax Bio Inc ended 2023 with $7.07 million in total assets and $0 in total liabilities. Its intangible assets were valued at $7.07 million while shareholder equity stood at $-7313000.00.

Baudax Bio Inc ended 2023 with $0 in deferred long-term liabilities, $12.37 million in other current liabilities, 26000.00 in common stock, $-179500000.00 in retained earnings and $2.13 million in goodwill. Its cash balance stood at $3.80 million and cash and short-term investments were $3.80 million. The company’s total short-term debt was $6,000,000 while long-term debt stood at $1.43 million.

Baudax Bio Inc’s total current assets stands at $4.11 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $3.84 million and inventory worth $0.

In 2023, Baudax Bio Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Baudax Bio Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$0.55

52-Week High

$37.7206

52-Week Low

$0.5

Analyst Target Price

$24

Baudax Bio Inc stock is currently trading at $0.55 per share. It touched a 52-week high of $37.7206 and a 52-week low of $37.7206. Analysts tracking the stock have a 12-month average target price of $24.

Its 50-day moving average was $1.2 and 200-day moving average was $5.44 The short ratio stood at 0.04 indicating a short percent outstanding of 0%.

Around 6.2% of the company’s stock are held by insiders while 4600.7% are held by institutions.